X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2023/07/24/2709420/0/en/Overland-ADCT-BioPharma-Announces-NMPA-Accepts-Biologics-License-Application-and-Grants-Priority-Review-for-ZYNLONTA-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Ly.html
https://www.fiercepharma.com/pharma/adc-therapeutics-pulls-plug-zynlonta-study-after-fda-partial-hold#:~:text=ADC%20Therapeutics%20pulls%20the%20plug%20on%20Zynlonta%20study%20after%20partial%20FDA%20hold,-By%20Zoey%20Becker&text=A%20week%20after%20ADC%20Therapeutics,an%20FDA%20partial%20clinical%20hold.
https://www.reuters.com/business/healthcare-pharmaceuticals/adc-therapeutics-pauses-enrolment-mid-stage-trial-cancer-therapy-2023-07-11/
https://www.globenewswire.com/news-release/2023/06/09/2685451/0/en/ADC-Therapeutics-Announces-Updated-LOTIS-2-Results-Demonstrating-Durable-Long-Term-Responses-of-ZYNLONTA-in-Relapsed-Refractory-DLBCL.html
https://www.ema.europa.eu/en/documents/overview/zynlonta-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/zynlonta-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/zynlonta-loncastuximab-tesirine-approved-in-the-eu-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-301707992.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761196
https://www.biopharmadive.com/news/adc-therapeutics-cuts-deal-with-sobi-to-broaden-reach-of-cancer-drug/626896/
https://www.biospace.com/article/releases/adc-therapeutics-announces-exclusive-license-with-mitsubishi-tanabe-pharma-corporation-to-develop-and-commercialize-zynlonta-loncastuximab-tesirine-lpyl-in-japan/?s=71
https://www.businesswire.com/news/home/20210618005064/en/ADC-Therapeutics-Presents-Updated-ZYNLONTA%E2%84%A2-loncastuximab-tesirine-lpyl-Clinical-Data-at-16th-Annual-International-Conference-on-Malignant-Lymphoma
https://www.businesswire.com/news/home/20210107005169/en/ADC-Therapeutics-Initiates-Expanded-Access-Program-for-Loncastuximab-Tesirine-in-the-U.S.
https://www.globenewswire.com/news-release/2020/12/07/2140427/0/en/VASCEPA-Icosapent-Ethyl-Related-Scientific-Findings-to-Be-Presented-at-National-Lipid-Association-NLA-Scientific-Sessions-2020.html
https://www.businesswire.com/news/home/20201207005264/en/ADC-Therapeutics-Announces-Updated-Clinical-Data-on-Lead-Antibody-Drug-Conjugate-Programs-Loncastuximab-Tesirine-Lonca-and-Camidanlumab-Tesirine-Cami-Presented-at-62nd-American-Society-of-Hematology-Annual-Meeting
https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/
https://www.fiercebiotech.com/biotech/ipo-check-now-adc-therapeutics-files-for-lonca-approval
https://www.businesswire.com/news/home/20200605005242/en/ADC-Therapeutics-Host-Conference-Call-Highlight-Loncastuximab
https://endpts.com/led-by-biontech-six-biotechs-line-up-for-october-ipos/
https://www.fiercebiotech.com/biotech/swiss-biotech-adc-therapeutics-guns-for-150m-ipo
https://www.fiercebiotech.com/medtech/adc-therapeutics-taps-freenome-to-chart-biomarkers-for-its-lead-lymphoma-drug
https://www.biospace.com/article/adc-therapeutics-adds-103-million-to-series-e-to-total-303-million/
https://www.fiercebiotech.com/biotech/adc-therapeutics-bumps-up-series-e-by-76m-preps-lead-drug-for-2020-filing
https://globenewswire.com/news-release/2018/12/05/1662163/0/en/ADC-Therapeutics-Presents-Updated-Data-from-Clinical-Trials-of-Novel-Antibody-Drug-Conjugates.html
https://globenewswire.com/news-release/2018/11/27/1657096/0/en/ADC-Therapeutics-Announces-First-Patients-Dosed-in-Phase-I-II-Clinical-Trial-of-ADCT-602-in-Relapsed-or-Refractory-B-cell-Acute-Lymphoblastic-Leukemia.html
https://www.fiercepharma.com/manufacturing/manufacturing-news-note-pci-and-adc-bio-add-to-manufacturing-recalls-up
https://endpts.com/after-mega-round-investment-adc-therapeutics-cans-phi-trial-in-her2/
https://www.biospectrumasia.com/news/26/9939/adc-bio-signs-agreement-with-sector-specialists-whp.html
Market Place
Share 
